AGA-(C8R) HNG17, humanin derivative

AGA-(C8R) HNG17, humanin derivative;

AGA-(C8R) HNG17, Humanin derivative 是一种有效的人类蛋白 (HN) 的衍生物。AGA-(C8R) HNG17, Humanin derivative 可完全抑制老年痴呆症相关损害引起的神经元细胞死亡。

AGA-(C8R) HNG17, humanin derivativeamp;;

AGA-(C8R) HNG17, humanin derivative Chemical Structure

CAS No. : 875910-01-3

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

AGA-(C8R) HNG17, humanin derivative 的其他形式现货产品:

AGA-(C8R) HNG17, humanin derivative TFA

生物活性

AGA-(C8R) HNG17, Humanin derivative is a potent humanin (HN) derivative. AGA-(C8R) HNG17, Humanin derivative completely suppresses neuronal cell death by Alzheimer’s disease-relevant insults[1].

分子量

1736.02

Formula

C78H134N20O24

CAS 号

875910-01-3

Sequence Shortening

PAGASRLLLLTGEIDLP

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Chiba T, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer’s disease-relevant insults in vitro and in vivo. J Neurosci. 2005 Nov 2;25(44):10252-61.

Difelikefalin(Synonyms: CR-845 FE-202845)

Difelikefalin (Synonyms: CR-845; FE-202845) 纯度: 99.65%

Difelikefalin (CR-845; FE-202845) 是周边限制性的,选择性的 κ 阿片受体 (KOR) 激动剂。Difelikefalin 具有抗炎作用,并在慢性肾脏病等疾病中具有调节瘙痒的潜力。

Difelikefalin (Synonyms: CR-845;  FE-202845)

Difelikefalin Chemical Structure

CAS No. : 1024828-77-0

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥5680 In-stock
5 mg ¥3800 In-stock
10 mg ¥6000 In-stock
25 mg ¥12000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Difelikefalin 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Neuronal Signaling Compound Library
  • FDA-Approved Drug Library
  • Drug Repurposing Compound Library
  • Neurotransmitter Receptor Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Peptide Library

生物活性

Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease[1][2].

IC50 & Target

kappa opioid receptor (KOR)[1]

体外研究
(In Vitro)

Difelikefalin (CR-845; FE-202845) does not penetrate the blood-brain barrier. Difelikefalin does not bind to mu opioid receptors or any other receptors beside KORs[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

679.85

Formula

C36H53N7O6

CAS 号

1024828-77-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (147.09 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4709 mL 7.3546 mL 14.7091 mL
5 mM 0.2942 mL 1.4709 mL 2.9418 mL
10 mM 0.1471 mL 0.7355 mL 1.4709 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.68 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.68 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.68 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Steven Fishbane, et al. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney Int Rep. 2020 Jan 28;5(5):600-610.

    [2]. Steven Fishbane, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients With Pruritus. N Engl J Med. 2020 Jan 16;382(3):222-232.

  • [1]. Steven Fishbane, et al. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney Int Rep. 2020 Jan 28;5(5):600-610.

    [2]. Steven Fishbane, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients With Pruritus. N Engl J Med. 2020 Jan 16;382(3):222-232.

AGA-(C8R) HNG17, humanin derivative TFA

AGA-(C8R) HNG17, humanin derivative TFA; 纯度: 95.50%

AGA-(C8R) HNG17, humanin derivative TFA 是一种有效的人类蛋白 (HN) 的衍生物。AGA-(C8R) HNG17, humanin derivative 可完全抑制老年痴呆症相关损害引起的神经元细胞死亡。

AGA-(C8R) HNG17, humanin derivative TFAamp;;

AGA-(C8R) HNG17, humanin derivative TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ¥2500 In-stock
10 mg ¥4200 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

AGA-(C8R) HNG17, humanin derivative TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

AGA-(C8R) HNG17, humanin derivative TFA is a potent humanin (HN) derivative. AGA-(C8R) HNG17, humanin derivative completely suppresses neuronal cell death by Alzheimer’s disease-relevant insults[1].

分子量

1850.04

Formula

C80H135F3N20O26

Sequence

Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro

Sequence Shortening

PAGASRLLLLTGEIDLP

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

H2O : 20 mg/mL (10.81 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.5405 mL 2.7026 mL 5.4053 mL
5 mM 0.1081 mL 0.5405 mL 1.0811 mL
10 mM 0.0541 mL 0.2703 mL 0.5405 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Chiba T, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer’s disease-relevant insults in vitro and in vivo. J Neurosci. 2005 Nov 2;25(44):10252-61.